Loading clinical trials...
Loading clinical trials...
The purpose of this study is to determine the efficacy and safety of a buprenorphine/naloxone sublingual tablet formulation as an office-based therapy for opiate dependence treatment.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Collaborators
NCT07052175 · Substance-related Disorders
NCT03745339 · Opioid-Related Disorders, Drug Addiction
NCT05336188 · Opioid-Related Disorders, Mobile Applications, and more
NCT06560866 · Substance-Related Disorders
NCT06676059 · Alcoholism, Substance-Related Disorders
University of Pennsylvania
Philadelphia, Pennsylvania
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions